While the usefulness of measuring the plasma levels of brain natriuretic peptide (BNP) in cases with worsening heart failure and severe heart failure has already been established, the benefits of evaluation of this parameter in asymptomatic stable patients with left ventricular dysfunction is still under debate. Left ventricular function was evaluated in 141 ambulatory outpatients with a previous history of myocardial infarction not associated with symptoms of heart failure for at least one year. The plasma BNP level was also determined in these patients for comparative study. No correlation between the plasma level of BNP and EF was noted in the normal-EF group, while a negative correlation between the two parameters was observed in the low-EF group (Y = 0.439 -0.000266X) (R2 = 0.244, P < 0.0001). The sensitivity was 91.5%, specificity 56.3%, positive predictive accuracy value 61.9%, and negative predictive accuracy value 83.8% for a plasma BNP cut-off level of 89.0 pg/mL.
BRAIN natriuretic peptide (BNP) is known to be secreted mainly from the myocardium in acute heart failure and chronic heart failure, to show more marked variation in levels than is known for other neurohumoral factors, 1) and to be correlated with indices of left ventricular functions, including pulmonary artery wedge pressure and left ventricular ejection fraction (EF).
2) Measurement of the plasma BNP level has been considered to be useful for not only making a diagnosis of heart failure, but also for objective monitoring of the therapeutic success. In cases of myocardial infarction (MI) as well, the plasma BNP level in the acute stage of MI is known to be an excellent predictive factor of the prognosis, regardless of the left ventricular EF, 3) and the plasma BNP level measured 3-4 weeks after acute MI (AMI) is known to be a useful independent predictive factor of AMI and cardiac death. 4) However, there have also been reports suggesting that measurement of the plasma level of BNP might be useful as a screening test for asymptomatic ventricular dysfunction in stable coronary artery disease patients. 5, 6) As described above, while the usefulness of measuring the plasma levels of BNP in worsening and severe heart failure patients has already been established, the usefulness of estimation of the plasma BNP levels in asymptomatic stable patients with left ventricular dysfunction is still under debate. Therefore, the relationship between plasma BNP concentrations and left ventricular functions in asymptomatic stable patients with a previous history of MI was investigated in this study.
METHODS

Subjects:
The study was conducted as a cross-sectional study, and included 141 ambulatory outpatients with a previous history of myocardial infarction, who did not have any symptoms of heart failure [Class I of the New York Heart Association classification of cardiac performance (NYHA classification)] for at least one year (4.5 ± 3.2 years, on average). Left ventricular function in these patients was evaluated by echocardiography, and the plasma BNP levels were also measured. Blood sampling: Prior to the collection of the blood samples, the patients were instructed to fast overnight, except for taking their regular medications. On the morning of the blood collection, venous blood samples for measurement of the plasma BNP levels were collected after the patients had rested in the sitting position for 30 minutes. The blood samples were immediately transferred into icecooled glass tubes containing anticoagulants (disodium ethylenediamine tetraacetic acid and aproptinin), centrifuged at 30,000g for 10 minutes at 4°C, and the plasma samples were stored frozen at -80°C until analysis. The plasma BNP level was measured using a high sensitivity radioimmunoassay kit (E-test "TOSOH" II (BNP) (TOSOH AIA Co. Ltd., Japan). Echocardiography: The echocardiographic measurements were performed by a cardiologist who was unaware of the purpose of the measurements. The left ventricular EF was calculated by the method of Simpson (Area-Trace method). The subjects were divided into a low-EF group and a normal-EF group on the basis of the median value of the EF by echocardiography, and the background characteristics were compared between these two groups to investigate the correlation between EF and the plasma BNP level.
2) A receiver operating characteristic curve (ROC curve) for the ability of plasma BNP level to detect left ventricular dysfunction was constructed to assess the sensitivity and specificity of plasma BNP level throughout the range of concentrations to detect left ventricular dysfunction. The area under the curve provides a measure of the diagnostic accuracy of the test. Statistical analysis: Continuous data are expressed as the mean ± standard deviation (SD), and categorical data as a percentage. All statistical analyses were performed using commercially available statistical software (SAS Institute Inc., Cary, NC, USA). Univariate analysis was conducted using the unpaired MannWhitney U test. Categorical data were compared using the chi-square test. Linear regression analysis was used to determine the correlation between continuous variables. The optimum concentration of plasma BNP for calculation of positive and negative predictive accuracies was obtained from the ROC analysis by addition. A P value of less than 0.05 was considered to denote statistical significance. Ethical considerations: The data were managed using only the initials of the subjects. The purpose of the present study was explained to all subjects, and consent for the use of personal data under strict observance of privacy was obtained from each subject. 
RESULTS
Patient characteristics:
Comparison according to the EF calculated from the echocardiographic data (Table) . The plasma BNP level was significantly higher in the low-EF group (< 0.55) than in the normal-EF group (≥ 0.55), but there was no difference between the two groups in terms of the age, sex distribution, complications, vascular sites responsible for the lesion, lipid profile, or medication status. (Figures 1 and 2 ) There was a negative correlation between the EF and plasma BNP (Y = 0.439 -0.0002663X (R2 = 0.248, P < 0.0001)) in the low-EF group, while there was no correlation between these two parameters in the normal-EF group.
Outcome:
1) Comparison according to the EF
2) Figure 3 shows the ROC curve of various concentrations of plasma BNP in the diagnosis of left ventricular dysfunction. The sensitivity was 91.5%, specificity 56.3%, positive predictive accuracy value 61.9%, and negative predictive accuracy value 83.8% for a plasma BNP cut-off level of 89.0 pg/mL.
DISCUSSION
The plasma BNP level can be objectively measured during routine medical examination, and this parameter is useful for making a diagnosis of heart failure, estimating the severity of heart failure, and predicting the outcome of patients with heart failure. The treatment guidelines for chronic heart failure proposed by the Japanese Society of Cardiology contain the following description: "Measurement of BNP concentration has been approved for health insurance reimbursement under the diagnostic category of heart failure in Japan, and has been shown to be useful in the diagnosis and management of heart failure". Plasma BNP is also a useful index of therapeutic outcome during drug treatment for heart failure 7) and a response to abnormal wall stress from severe ventricular arrhythmias. 8) Some investigations in Japanese subjects have shown that plasma BNP is useful as an independent factor for estimation of the outcome and prediction of sudden death. 9, 10) On the other hand, plasma BNP has been reported to increase with increases in the grade of severity of heart disease according to the NYHA classification in a way similar to the plasma levels of ANP, cGMP, and norepinephrine.
11) One possible reason seems to be that the sympathetic nerves are activated by the presence of cardiac dysfunction to induce the secretion of neurohumoral factors. However, even among patients with a previous history of heart disease (Class I of the NYHA classification), there would be no difference in the plasma BNP level between patients and healthy people among those without heart failure. However, a significant number of patients with ischemic heart diseases, including previous MI, continue to show high BNP levels even when their condition is asymptomatic and they can be categorized as belonging to Class I of the NYHA classification of the severity of heart disease.
6) The subjects in the present study were asymptomatic and had a previous history of NYHA Class I MI. Some reports have shown the absence of any correlation between elevated plasma BNP levels and poor ejection fraction in stable asymptomatic patients with coronary artery disease 5) and that measurement of the plasma BNP level is not suitable as a screening test in the evaluation of left ventricular functions. 12) These points are still under discussion. When the subjects were divided into a normal-EF group (≥ 0.55) and low-EF group (< 0.55) in the present study, the low-EF group showed high plasma BNP levels, suggesting a negative correlation between the EF and plasma BNP level. In other words, it was suggested that measurement of the plasma BNP level may allow the EF to be estimated in cases of left ventricular dysfunction, even in asymptomatic clinically stable patients with a previous history of MI. We defined the low-EF group as having a left ventricular EF < 0.55 on the basis of the median value in this study, however, further discussion is necessary in order to be able to prove whether it is reasonable.
It is difficult to extrapolate the results of the present study directly for the management of asymptomatic clinically stable patients with a previous history of MI because of the cross-sectional study design. However, the results revealed that Vol 46 No 6 the EF was decreased in patients with an elevated BNP level, and the decrease in EF was inversely proportional to the degree of elevation of the plasma BNP level, and furthermore, that the plasma BNP level was significantly elevated in patients with a decline in EF, showing a negative correlation between the EF and plasma BNP concentration. These results are of great significance in actual clinical settings. Making a diagnosis of heart failure is not necessarily easy. General practitioners, in particular, who have no specialized knowledge of cardiology, often encounter difficult cases. Unlike echocardiography or imaging procedures, the plasma BNP concentration can be measured simply by blood sampling alone on an outpatient basis, and measurement may, therefore, play an important role in routine medical examination as an objective and useful marker of failing heart function.
CONCLUSION
The plasma BNP level was found to serve as a good guideline for decisions regarding the time of treatment on an inpatient basis and of hospital discharge in acute myocardial infarction patients. The results suggest that measurement of the plasma BNP level may be particularly useful in patients with a previous history of myocardial infarction who are asymptomatic but have a low EF. Early detection and treatment of such asymptomatic patients is considered to be useful for decreasing the number of myocardial infarction patients developing severe heart failure and improving the outcomes of these patients.
